ACTRN12620000008921进行中（未招募）1 期
A Phase I, Open-Label, Multiple Ascending Dose Study of the Safety and Tolerability of T3011 in advanced Cutaneous or Subcutaneous Malignancies
Theravir Pty Ltd0 个研究点目标入组 12 人开始时间: 2020年1月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. See Age criteria
- •2. Histologically confirmed diagnosis of cutaneous OR subcutaneous advanced malignancy.
- •3. Measurable disease per RECIST version 1.1.
- •4. Must have at least 1 tumour lesion with a longest dimension of greater than or equal to 10 mm (greater than or equal to 15 mm for the short axis for malignant lymph node lesions) that can be easily palpated or detected by ultrasound to facilitate IT injection of T3011 (ie, tumour in skin, muscle, subcutaneous tissue, or accessible lymph node).
- •5. Disease progression after standard-of-care (SOC) therapy or in the opinion of the Investigator unlikely to benefit from SOC therapy.
- •6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- •7. Life expectancy > 12 weeks.
- •8. Adequate bone marrow function defined by ANC of greater than or equal to 1.5 × 10^9/L, platelet count of greater than or equal to 100.0 × 10^9/L, and hemoglobin of greater than or equal to 90 g/L (with or without transfusion).
- •9. Adequate hepatic function defined as serum total bilirubin < 2.5 × ULN, AST/ALT of less than or equal to 2.5 × ULN (or less than or equal to 5 × ULN in participants with liver metastases).
- •10. Adequate renal function defined as creatinine clearance > 50 mL/min as determined by the Cockcroft-Gault equation.
- •11. Female participants must be surgically sterile (or have a monogamous partner who is surgically sterile), or be least 2 years postmenopausal, or commit to using 2 acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 6 months following the last dose of study treatment. Male participants must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 6 months following the last dose of study treatment.
- •12. Women of childbearing potential (WCBP) must have a negative serum pregnancy test at Screening within 7 days of dosing with T3011.
- •13. Last dose of previous anticancer therapy greater than or equal to 28 days, radiotherapy > 21 days (concurrent targeted palliative radiotherapy is allowed to non-injected lesions during T3011 treatment), or surgical intervention > 21 days prior to the first dose of T3011.
- •14. Resolution of all prior anticancer therapy toxicities (except for alopecia) to less than or equal to Grade 1.
- •Note: patients previously treated with immunotherapy who have endocrinopathies may enrol if on adequate replacement therapy.
- •15. Willingness to provide pre- and post-treatment fresh tumour biopsy specimens.
- •16. Capable of understanding and complying with protocol requirements.
- •17. Signed and dated institutional review board/independent ethics committee-approved informed consent form before any protocol-directed screening procedures are performed
排除标准
- •Have only tumours with severe fibrosis and therefore not injectable.
- •2. Patients with injectable tumours impinging upon major airways or blood vessels.
- •3. Prior treatment with another oncolytic virus or cellular therapy.
- •4. Requires continued concurrent therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir).
- •5. Systemic therapy with immunosuppressive agents within 28 days before the start of T3011 treatment; topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement for patients with adrenal insufficiency are allowed.
- •6. Live vaccines within 4 weeks of initiation of study treatment.
- •7. Primary or acquired immunodeficient states (leukaemia, lymphoma, human immunodeficiency virus (HIV)/AIDS).
- •8. Pregnant or lactating.
- •9. Prior organ transplantation.
- •10. Active hepatitis B virus, hepatitis C virus, and HIV infection or a positive serological test at Screening within 14 days of dosing with T3011. Positive for HCV Ab only when HCV RNA positive at Screening. Patients who are HBsAg+ and/or HBcAb+ and have a DNA load <2000 IU/mL (10^4 copies/mL) are considered eligible to participate in the study.
- •11. Active autoimmune disease or medical conditions requiring chronic steroid
- •(ie, > 10 mg/day prednisone or equivalent) or immunosuppressive therapy; patients with a prior history of autoimmune disease may be eligible following discussion with and written approval from the Medical Monitor.
- •12. History of or current central nervous system metastases (brain imaging [eg, by CT scan, PET scan, MRI scan, etc., per site standards] completed within 3 months of Screening [required for all participants]).
- •13. History of seizure disorders within 6 months of Screening.
- •14. Active oral herpes lesion at Screening.
- •15. Baseline pulse oximetry < 92% on room air.
- •16. Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids.
- •17. Congestive heart failure (> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest), or clinically significant cardiac arrhythmias.
- •18. History of allergic reactions attributed to compounds of similar biological composition.
- •19. Known or activie suspected infections with SARS-CoV-2 virus .
- •20. Other systemic conditions or organ abnormalities that, in the opinion of the Investigator, may interfere with the conduct and/or interpretation of the current study.
研究者
相似试验
进行中（未招募）
1 期
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric DisordersPsychiatric DisordersMedDRA version: 20.0Level: SOCClassification code 10037175Term: Psychiatric disordersSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: HLTClassification code 10037177Term: Infancy, childhood and adolescence psychiatric disorders NECSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2018-001064-30-BGACADIA Pharmaceuticals Inc.36
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 20.0Level: LLTClassification code 10008231Term: Cervical cancer recurrentSystem Organ Class: 100000004864EUCTR2017-000556-26-FRAgenus Inc.85
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 21.1Level: LLTClassification code 10008231Term: Cervical cancer recurrentSystem Organ Class: 100000004864EUCTR2017-000556-26-PLAgenus Inc.200
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 20.0 Level: LLT Classification code 10008231 Term: Cervical cancer recurrent System Organ Class: 100000004864EUCTR2017-000556-26-ESAgenus Inc.150
进行中（未招募）
1 期
Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical CancerMetastatic or Locally Advanced Solid Tumors and Cervical CancerMedDRA version: 20.0Level: LLTClassification code 10008231Term: Cervical cancer recurrentSystem Organ Class: 100000004864EUCTR2017-000556-26-LTAgenus Inc.150